Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma.

Trial Profile

Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Carboplatin (Primary) ; Oblimersen (Primary) ; Paclitaxel (Primary)
  • Indications Uveal neoplasms
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Sep 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
    • 08 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
    • 08 Nov 2012 New source identified and integrated (M.D. Anderson Cancer Center; 2010-0188).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top